ASCO GI 2023 Conference Coverage
Playback speed
10 seconds
Phase 3 Randomized SUNLIGHT Study: Trifluridine/Tipiracil + Bevacizumab for 3L Treatment of Refractory mCRC
By
ASCO GI 2023 Conference Coverage
FEATURING
Josep Tabernero
By
ASCO GI 2023 Conference Coverage
FEATURING
Josep Tabernero
0 views
January 25, 2023
Disclaimer: This video was recorded prior to FDA approval of trifluridine and tipiracil with bevacizumab ...
read more ↘ on August 2, 2023 for mCRC.
↖ read less
read more ↘ on August 2, 2023 for mCRC.
↖ read less
Comments 0
Login to view comments.
Click here to Login
Videos